Ownership Capital B.V. Sells 27,764 Shares of Illumina, Inc. (NASDAQ:ILMN)

Ownership Capital B.V. lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 813,734 shares of the life sciences company’s stock after selling 27,764 shares during the quarter. Illumina makes up 2.5% of Ownership Capital B.V.’s holdings, making the stock its 18th biggest holding. Ownership Capital B.V. owned approximately 0.51% of Illumina worth $113,304,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ILMN. Global Retirement Partners LLC grew its stake in shares of Illumina by 36.5% during the third quarter. Global Retirement Partners LLC now owns 714 shares of the life sciences company’s stock worth $99,000 after buying an additional 191 shares during the last quarter. Czech National Bank grew its stake in shares of Illumina by 47.8% in the third quarter. Czech National Bank now owns 27,668 shares of the life sciences company’s stock worth $3,798,000 after purchasing an additional 8,953 shares during the last quarter. Slow Capital Inc. grew its stake in shares of Illumina by 6.6% in the third quarter. Slow Capital Inc. now owns 35,155 shares of the life sciences company’s stock worth $4,826,000 after purchasing an additional 2,169 shares during the last quarter. Linden Thomas Advisory Services LLC grew its stake in shares of Illumina by 121.8% in the third quarter. Linden Thomas Advisory Services LLC now owns 9,077 shares of the life sciences company’s stock worth $1,246,000 after purchasing an additional 4,984 shares during the last quarter. Finally, Chevy Chase Trust Holdings LLC grew its stake in shares of Illumina by 2.8% in the third quarter. Chevy Chase Trust Holdings LLC now owns 533,414 shares of the life sciences company’s stock worth $73,227,000 after purchasing an additional 14,342 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the acquisition, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.17% of the stock is currently owned by company insiders.

Illumina Stock Up 1.0 %

Shares of NASDAQ ILMN traded up $1.23 during trading on Friday, hitting $122.28. 829,331 shares of the company traded hands, compared to its average volume of 1,470,247. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $213.91. The firm has a market capitalization of $19.47 billion, a price-to-earnings ratio of -16.66 and a beta of 1.19. The business’s fifty day moving average is $131.51 and its 200 day moving average is $127.39.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the prior year, the business posted $0.14 EPS. The firm’s revenue was up 3.6% compared to the same quarter last year. Equities research analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on ILMN. Royal Bank of Canada reissued an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a research note on Tuesday, April 9th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. TD Cowen lowered shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a report on Thursday, January 4th. Finally, Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Illumina in a report on Wednesday, April 10th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $167.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.